This website uses cookies
Read our Privacy policy and Terms of use for more information.
Jun 11, 2026
GLP-1s may influence depression through the gut while pharma companies look beyond Earth for innovation.
Jun 9, 2026
Researchers get removed from ADA conference after handing out a funding-cuts editorial, while obesity drug developers steal the spotlight in New Orleans.
Jun 4, 2026
Anti-aging biotech lands $435M, China dominates ASCO, and Lilly keeps writing billion-dollar checks.
Jun 2, 2026
Revolution Medicines earns a standing ovation at ASCO, Pfizer signs a $10B oncology partnership, and Lilly keeps its deal spree alive.
May 28, 2026
The FDA reassembles vaccine advisers, Lilly spends another $3.8B on biotech acquisitions, and Washington debates whether China licensing is becoming a national security risk.
May 26, 2026
Moderna heads back into the FDA arena, Lilly posts bariatric-level weight loss numbers, and biotech may be getting its own betting market.
May 21, 2026
BMS deploys Claude across 30,000 employees, Lilly files a bizarre rebate fraud lawsuit, and Takeda faces a landmark legal blow.
May 19, 2026
Revolution Medicines is drawing “next oncology titan” comparisons, pharma tariff exemptions get complicated, and FDA chaos continues.
May 14, 2026
Big Pharma is absent from Trump’s China trip, Novo drops fresh obesity data, and FDA Commissioner Marty Makary exits.
